By SPC News Staff
The FDA granted a new indication for galcanezumab-gnlm (Emgality, Lilly) solution for injection to treat episodic cluster headache in adults.
“For years, there have been few therapeutic options to offer patients for the treatment of episodic cluster headache. With today’s approval, physicians are now armed with an FDA-approved medication that has the potential to help patients living with this condition by reducing the frequency of cluster attacks,” said David